Continuous GHRH Plus GHRP-2 Infusion Restores GH and IGF-1 in Critically Ill Patients
Continuous combined GHRH and GHRP-2 infusion in critically ill patients restored GH secretion and raised IGF-1, offering a novel approach to combat ICU muscle wasting.
Quick Facts
What This Study Found
Continuous GHRH plus GHRP-2 infusion partially restored GH pulsatility and substantially raised IGF-1 levels in critically ill patients with suppressed somatotropic axes.
Key Numbers
How They Did This
Clinical trial using continuous IV infusion of combined GHRH and GHRP-2 in critically ill patients, measuring GH secretion profiles and IGF-1 levels.
Why This Research Matters
ICU muscle wasting significantly impacts recovery and survival. Restoring the GH/IGF-1 axis through secretagogues rather than GH injections may be safer and more effective.
The Bigger Picture
This study demonstrated a practical approach to combating ICU muscle wasting using physiological GH stimulation rather than supraphysiological GH replacement, which had shown concerning mortality in ICU studies.
What This Study Doesn't Tell Us
Clinical trial in heterogeneous critically ill population. Functional outcomes (muscle preservation, recovery) not assessed. Comparison to GH replacement not included.
Questions This Raises
- ?Does GH/IGF-1 restoration through secretagogues improve ICU outcomes?
- ?Is combined GHRH+GHRP-2 infusion safer than direct GH replacement in critical illness?
Trust & Context
- Key Stat:
- GH axis restored in ICU Combined GHRH+GHRP-2 continuous infusion restored GH pulsatility and substantially increased IGF-1 in critically ill patients
- Evidence Grade:
- Moderate clinical evidence demonstrating hormonal restoration in critically ill patients. Lacks functional outcome data.
- Study Age:
- Published in 1997, this study offered an alternative to direct GH replacement, which was later shown to increase mortality in ICU patients (1999 Finnish study).
- Original Title:
- The somatotropic axis in critical illness: effect of continuous growth hormone (GH)-releasing hormone and GH-releasing peptide-2 infusion.
- Published In:
- The Journal of clinical endocrinology and metabolism, 82(2), 590-9 (1997)
- Authors:
- Van den Berghe, G(10), de Zegher, F(5), Veldhuis, J D(13), Wouters, P, Awouters, M, Verbruggen, W, Schetz, M, Verwaest, C, Lauwers, P, Bouillon, R, Bowers, C Y
- Database ID:
- RPEP-00436
Evidence Hierarchy
Frequently Asked Questions
Why not just give GH directly to ICU patients?
A landmark 1999 study showed direct GH replacement actually increased mortality in ICU patients. Using secretagogues like GHRH+GHRP-2 instead stimulates the body's own GH production, which is self-limiting and may be safer.
Why combine GHRH with GHRP-2?
In critical illness, the GH axis is suppressed at multiple levels. GHRH acts on the pituitary and GHRP-2 acts on both the hypothalamus and pituitary through a different pathway. The combination restores GH release more effectively than either alone.
Read More on RethinkPeptides
Cite This Study
https://rethinkpeptides.com/research/RPEP-00436APA
Van den Berghe, G; de Zegher, F; Veldhuis, J D; Wouters, P; Awouters, M; Verbruggen, W; Schetz, M; Verwaest, C; Lauwers, P; Bouillon, R; Bowers, C Y. (1997). The somatotropic axis in critical illness: effect of continuous growth hormone (GH)-releasing hormone and GH-releasing peptide-2 infusion.. The Journal of clinical endocrinology and metabolism, 82(2), 590-9.
MLA
Van den Berghe, G, et al. "The somatotropic axis in critical illness: effect of continuous growth hormone (GH)-releasing hormone and GH-releasing peptide-2 infusion.." The Journal of clinical endocrinology and metabolism, 1997.
RethinkPeptides
RethinkPeptides Research Database. "The somatotropic axis in critical illness: effect of continu..." RPEP-00436. Retrieved from https://rethinkpeptides.com/research/van-1997-the-somatotropic-axis-in
Access the Original Study
Study data sourced from PubMed, a service of the U.S. National Library of Medicine, National Institutes of Health.
This study breakdown was produced by the RethinkPeptides research team. We analyze and report published research findings without making health recommendations. All interpretations are based solely on the published abstract and study data.